Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: 5-fluoruracil|DRUG: Granulocyte-colony stimulating growth factor|DRUG: Trastuzumab
Sponsor: Hellenic Oncology Research Group
Collaborators: University Hospital of Crete